Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2019 December;44(4) > Minerva Endocrinologica 2019 December;44(4):378-86

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Endocrinologica 2019 December;44(4):378-86

DOI: 10.23736/S0391-1977.19.03012-8

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin

Krystallenia I. ALEXANDRAKI 1 , Marina TSOLI 1, Georgios KYRIAKOPOULOS 2, Anna ANGELOUSI 1, Georgios NIKOLOPOULOS 1, Denise KOLOMODI 1, Gregory A. KALTSAS 1

1 Unit of Endocrinology, First Department of Internal Medicine, Laiko University Hospital, National and Kapodistrian University of Athens, Athens, Greece; 2 Department of Pathology, Evangelismos Hospital, Athens, Greece



Neuroendocrine neoplasms (NENs) of unknown primary origin (UPO-NENs) are advanced neoplasms constituting 11-22% of all NENs that by definition their primary tissue of origin has not been identified with standard diagnostic work-up. Delineating the primary site of origin of UPO-NENs has important implications for selecting the appropriate treatment and overall prognosis. The small bowel, followed by the lung and pancreas are the most prevalent primary sites of origin of UPO-NENs that are uncovered during an extensive and prolonged diagnostic work-up; however, a number of UPO-NENs may still remain occult even after prolonged follow-up. A number of diagnostic algorithms that incorporate histopathological, molecular, imaging (either morphological or functional imaging), and serum biomarkers can help to identify the primary tumor origin. It is expected that advances in these fields will help reduce significantly the number of UPO-NENs.


KEY WORDS: Neuroendocrine tumors; Unknown primary neoplasms; CDX2 transcription factor; Human TTF1 protein; 68Ga-DOTA-peptide

inizio pagina